Table 2.
Approved tyrosine kinase inhibitors in veterinary medicine, all drugs.
| Drug | Targets | Year Approved | Indication |
|---|---|---|---|
| Toceranib (Palladia®) | VEGF-R2 | 2009 | Patnaik grade 2 or 3, recurrent, cutaneous mast cell tumors with or without regional lymph node involvement in dogs |
| PDGF-Rα | |||
| Kit | |||
| Flt-3 | |||
| RET | |||
| JAK family | |||
| Masitinib (Kinavet-CA1®) | Kit | 2010 a | Nonresectable grade 2 and 3 cutaneous mast cell tumors in dogs that have not previously received radiotherapy and/or chemotherapy except corticosteroids |
| PDGF-Rα/β | |||
| Lyn | |||
| FGF-R3 | |||
| Oclacitinib (Apoquel®) | JAK1 | 2013 | Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 mos of age |
| JAK 2 |
a Conditional approval by the FDA expired in December 2015 and the drug is not commercially available in the US. The drug can only be obtained through the FDA’s personal import mechanism.